CN104271550B - 白桦脂醇的丙烯酸酯衍生物 - Google Patents

白桦脂醇的丙烯酸酯衍生物 Download PDF

Info

Publication number
CN104271550B
CN104271550B CN201280069633.7A CN201280069633A CN104271550B CN 104271550 B CN104271550 B CN 104271550B CN 201280069633 A CN201280069633 A CN 201280069633A CN 104271550 B CN104271550 B CN 104271550B
Authority
CN
China
Prior art keywords
compound
pharmaceutically acceptable
alkyl
acceptable salt
oxo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201280069633.7A
Other languages
English (en)
Chinese (zh)
Other versions
CN104271550A (zh
Inventor
N.韩
B.A.约翰斯
J.唐
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline China Investment Co Ltd
Original Assignee
GlaxoSmithKline China Investment Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/CN2011/002159 external-priority patent/WO2013091144A1/en
Application filed by GlaxoSmithKline China Investment Co Ltd filed Critical GlaxoSmithKline China Investment Co Ltd
Priority to CN201280069633.7A priority Critical patent/CN104271550B/zh
Publication of CN104271550A publication Critical patent/CN104271550A/zh
Application granted granted Critical
Publication of CN104271550B publication Critical patent/CN104271550B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/30—Halogen atoms or nitro radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/70—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/72—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms
    • C07C235/76—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton
    • C07C235/78—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton the carbon skeleton containing rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/34—Esters of acyclic saturated polycarboxylic acids having an esterified carboxyl group bound to an acyclic carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/61—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
    • C07J63/008—Expansion of ring D by one atom, e.g. D homo steroids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/02—Ortho- or ortho- and peri-condensed systems
    • C07C2603/52—Ortho- or ortho- and peri-condensed systems containing five condensed rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN201280069633.7A 2011-12-14 2012-12-14 白桦脂醇的丙烯酸酯衍生物 Expired - Fee Related CN104271550B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201280069633.7A CN104271550B (zh) 2011-12-14 2012-12-14 白桦脂醇的丙烯酸酯衍生物

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
CN2011002105 2011-12-14
CNPCT/CN2011/002105 2011-12-14
PCT/CN2011/002159 WO2013091144A1 (en) 2011-12-21 2011-12-21 Propenoate derivatives of betulin
CNPCT/CN2011/002159 2011-12-21
CN201280069633.7A CN104271550B (zh) 2011-12-14 2012-12-14 白桦脂醇的丙烯酸酯衍生物
PCT/US2012/069688 WO2013090683A1 (en) 2011-12-14 2012-12-14 Propenoate derivatives of betulin

Publications (2)

Publication Number Publication Date
CN104271550A CN104271550A (zh) 2015-01-07
CN104271550B true CN104271550B (zh) 2016-09-07

Family

ID=48613201

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201280069633.7A Expired - Fee Related CN104271550B (zh) 2011-12-14 2012-12-14 白桦脂醇的丙烯酸酯衍生物

Country Status (12)

Country Link
US (1) US9340513B2 (enExample)
EP (1) EP2791102B1 (enExample)
JP (1) JP6091520B2 (enExample)
KR (1) KR20140101869A (enExample)
CN (1) CN104271550B (enExample)
AU (1) AU2012352129B2 (enExample)
BR (1) BR112014014046A2 (enExample)
CA (1) CA2859032A1 (enExample)
ES (1) ES2584684T3 (enExample)
IN (1) IN2014CN04449A (enExample)
RU (1) RU2613554C2 (enExample)
WO (1) WO2013090683A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3387B1 (ar) 2011-12-16 2019-03-13 Glaxosmithkline Llc مشتقات بيتولين
KR20150093819A (ko) 2012-12-14 2015-08-18 글락소스미스클라인 엘엘씨 약제 조성물
WO2014105926A1 (en) 2012-12-31 2014-07-03 Hetero Research Foundation Novel betulinic acid proline derivatives as hiv inhibitors
US20170129916A1 (en) 2014-06-26 2017-05-11 Hetero Research Foundation Novel betulinic proline imidazole derivatives as hiv inhibitors
KR20170056702A (ko) 2014-09-26 2017-05-23 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 지효성 약제학적 조성물
CA2967601A1 (en) * 2014-11-14 2016-05-19 VIIV Healthcare UK (No.5) Limited Extended betulinic acid analogs
MA40886B1 (fr) 2015-02-09 2020-03-31 Hetero Research Foundation Nouveau triterpénone en c-3 avec des dérivés d'amide inverse en c-28 en tant qu'inhibiteurs du vih
WO2016147099A2 (en) 2015-03-16 2016-09-22 Hetero Research Foundation C-3 novel triterpenone with c-28 amide derivatives as hiv inhibitors
AR107512A1 (es) * 2016-02-04 2018-05-09 VIIV HEALTHCARE UK Nº 5 LTD Triterpenoides modificados en c-3 y c-17 como inhibidores del vih-1
WO2019150300A1 (en) 2018-02-02 2019-08-08 Glaxosmithkline Intellectual Property (No.2) Limited Crystalline forms of 4-(((3ar,5ar,5br,7ar,9s,11ar,11br,13as)-3a-((r)-2-((4-chlorobenzyl)(2-(dimethylamino)ethyl)amino)-1-hydroxyethyl)-1-isopropyl-5a,5b,8,8,11a-pentamethyl-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,11,11a,11b,12,13,13a-octadecahydro-2h-cyclopenta[a]chrysen-9-yl)oxy)-2,2-dimethyl-4-oxobutanoic acid

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008057420A2 (en) * 2006-11-03 2008-05-15 Panacos Pharmaceuticals, Inc. Extended triterpene derivatives
CN101328201A (zh) * 2008-07-29 2008-12-24 浙江大学 一种从桦树皮中提取白桦脂醇的方法
CN101704874A (zh) * 2009-11-26 2010-05-12 中国药科大学 五环三萜及其衍生物的二甲双胍盐、其制备方法及医药用途
CN101709322A (zh) * 2009-11-26 2010-05-19 浙江大学 生物催化白桦脂醇合成白桦脂酸的方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200628161A (en) * 2004-11-12 2006-08-16 Panacos Pharmaceuticals Inc Novel betulin derivatives, preparation thereof and use thereof
EP2231163A4 (en) * 2007-12-04 2012-10-31 Myriad Pharmaceuticals Inc COMPOUNDS AND THEIR THERAPEUTIC USE
MX2010007375A (es) * 2008-01-03 2010-09-30 Virochem Pharma Inc Nuevos derivados de lupano.
US8802727B2 (en) * 2009-07-14 2014-08-12 Hetero Research Foundation, Hetero Drugs Limited Pharmaceutically acceptable salts of betulinic acid derivatives
US9067966B2 (en) * 2009-07-14 2015-06-30 Hetero Research Foundation, Hetero Drugs Ltd. Lupeol-type triterpene derivatives as antivirals
WO2011100308A1 (en) * 2010-02-11 2011-08-18 Glaxosmithkline Llc Derivatives of betulin

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008057420A2 (en) * 2006-11-03 2008-05-15 Panacos Pharmaceuticals, Inc. Extended triterpene derivatives
CN101328201A (zh) * 2008-07-29 2008-12-24 浙江大学 一种从桦树皮中提取白桦脂醇的方法
CN101704874A (zh) * 2009-11-26 2010-05-12 中国药科大学 五环三萜及其衍生物的二甲双胍盐、其制备方法及医药用途
CN101709322A (zh) * 2009-11-26 2010-05-19 浙江大学 生物催化白桦脂醇合成白桦脂酸的方法

Also Published As

Publication number Publication date
US9340513B2 (en) 2016-05-17
RU2613554C2 (ru) 2017-03-17
WO2013090683A1 (en) 2013-06-20
CA2859032A1 (en) 2013-06-20
BR112014014046A2 (pt) 2017-06-13
KR20140101869A (ko) 2014-08-20
CN104271550A (zh) 2015-01-07
EP2791102A4 (en) 2015-04-22
EP2791102B1 (en) 2016-05-18
IN2014CN04449A (enExample) 2015-09-04
US20140350032A1 (en) 2014-11-27
ES2584684T3 (es) 2016-09-28
JP6091520B2 (ja) 2017-03-08
EP2791102A1 (en) 2014-10-22
AU2012352129A1 (en) 2014-08-07
AU2012352129B2 (en) 2016-02-04
RU2014122866A (ru) 2016-02-10
JP2015501846A (ja) 2015-01-19

Similar Documents

Publication Publication Date Title
CN104271550B (zh) 白桦脂醇的丙烯酸酯衍生物
EP2791103B1 (en) Derivatives of betulin
WO2013020245A1 (en) Carbonyl derivatives of betulin
EP3762396A1 (en) Compounds useful in hiv therapy
WO2013091144A1 (en) Propenoate derivatives of betulin
WO2013020246A1 (en) Methylene derivatives of betulin
CA2998828A1 (en) Compounds with hiv maturation inhibitory activity
CN108026140A (zh) 用于预防或治疗hiv感染的白桦脂醇衍生物
CN108026139A (zh) 用于预防或治疗hiv感染的白桦脂醇衍生物
HK1197399A (en) Derivatives of betulin
HK1197399B (en) Derivatives of betulin
NZ625516B2 (en) Derivatives of betulin

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20160907

Termination date: 20191214